Related Experiment Video

Updated: Jul 31, 2026

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

Visfatin levels in patients with severe pneumonia

Xie Juan¹, Yi-Ming Lu¹, Jin-Dong Shi¹

¹Department ofRespiration(Xie J, Long W), Department of Emergency (Shi JD), Fifth People's Hospital Affiliated to Fudan University, Shanghai 200240, China; Emergency Department, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China (Lu YM); Emergency Department, Central Hospital, Minhang District, Ruijin Hospital, Shanghai, China (Deng XQ).

World Journal of Emergency Medicine

|September 13, 2014

Abstract

Background:

As a cytokine highly expressed in internal organs, visfatin could be used as a biomarker of systemic inflammation response for chronic obstructive pulmonary diseases, but few studies have reported the use of visfatin in severe pneumonia. The present study was undertaken to determine the plasma levels of visfatin in patients with severe pneumonia.

Methods:

A total of 70 patients, including 40 patients with severe pneumonia (group A) and 30 patients with non severe pneumonia (group B) who had been admitted to the ICU from June 2009 to June 2010, were enrolled in this prospective study. And another 30 healthy physical examinees served as healthy controls (group C). Patients were excluded if they suffered from severe diseases of the heart, brain and kidney, cancers, autoimmune diseases, or received special treatment in the latest month. The plasma levels of visfatin, IL-6, IL-8 and TNF-α were measured by ELISA, while the level of CRP was determined by immuneturbidimetry, and the routine blood test was performed. Blood gas analysis and Acute Physiology and Chronic Health Evaluation II (APACHE II) were performed in patients with pneumonia. Comparisons between the groups were conducted by Student's t test, ANOVA or nonparametric test. Correlation analysis was carried out by Pearson's correlation test or Spearman's rank-order correlation test.

Results:

The plasma level of visfatin in group A was significantly higher than that in groups B and C (P<0.001), and the level of visfatin in group B was significantly higher than that in group C (P<0.001). The plasma level of visfatin was positively correlated with CRP, TNF-α, APACHE II and PMN% in patients with severe pneumonia (rho =0.653, r=0.554, r=0.558, r=0.484, respectively, P<0.05 for all), while it was negatively correlated with PaO2 and PaO2/FiO2 (rho =-0.422, r=-0.543, respectively, P<0.05 for all).

Conclusion:

Visfatin may be involved in the systematic inflammation response in patients with severe pneumonia as a pro-inflammatory cytokine, and it is valuable in assessing the severity of pneumonia..

Keywords:

Acute Physiology and Chronic Health Evaluation II (APACHE II)C-reactive protein Granulocyte percent (PMN%)Interleukin-6 Interleukin-8 Severe pneumonia Tumor necrosis factor-a Visfatin

More Related Videos

Phase-Resolved Functional Lung MRI for Pulmonary Ventilation and Perfusion (V/Q) Assessment

Phase-Resolved Functional Lung MRI for Pulmonary Ventilation and Perfusion (V/Q) Assessment

Published on: August 9, 2024

Modeling Dysplastic and Functional Lung Alveolar Repair after Influenza Infection

Modeling Dysplastic and Functional Lung Alveolar Repair after Influenza Infection

Published on: September 19, 2025

Related Concept Videos

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Acute Respiratory Failure-II

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Articles linked to this work by shared authors, journal, and citation graph.

The mitophagy-inflammasome axis: a shared pathological hub in Alzheimer's and Parkinson's diseases.

Translational neurodegeneration·2026

In Situ Sonoafterglow Supramolecular Hydrogel From Natural Substrate for Post-Surgical Glioblastoma Treatment.

Angewandte Chemie (International ed. in English)·2026

Study on the Carbonation Behavior of Steel Slag in the SiC-K2SiO3 System Assisted by Microwave Heating.

Materials (Basel, Switzerland)·2026

Per- and polyfluoroalkyl substances in breast milk and child growth trajectories during the first two years: A prospective birth cohort study in Nanjing, China.

Journal of hazardous materials·2026

Tobacco smoke exposure and spine fracture risk in US adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 1999-2010, 2013-2014, 2017-2020.

Tobacco induced diseases·2026

Exploratory meta-analysis of the effect of music intervention on arousal promotion in patients with disorders of consciousness: evidence from controlled studies.

Frontiers in neuroscience·2026

See all related articles